Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics HSDD Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Hypoactive Sexual Desire Disorder (HSDD) Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity limits for Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder and related female sexual interest/arousal disorder in commercial plan members.

    Policy Summary
    PayerPrime Therapeutics
    PolicyHypoactive Sexual Desire Disorder (HSDD) Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 15, 2026
    Next Review DateN/A
    Key ActionFor initial approval, document that the patient tried other treatment modalities and had an inadequate response.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Target agents
    30/30 daysAddyi limit
    8/30 daysVyleesi limit
    6 monthsInitial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Renewal approval

    General Coverage Requirements

    Initial Therapy

    Target agents will be approved when ALL of the following are met.

    Initial therapy requirements

    • Benefit coverage: The patient's benefit plan covers the requested agent.
    • Agent-specific eligibility

      • Vyleesi eligibility: The requested agent is Vyleesi and the patient is premenopausal.Premenopausal
      • Addyi eligibility

        • Age: The requested agent is Addyi and the patient is less than 65 years of age.Age <65 years
        • Sex appropriateness

          • The patient's sex is female.
          • Addyi is medically appropriate for the patient's sex.
    • Diagnosis and clinical criteria

      • Qualifying diagnosis

        • The patient has acquired, generalized hypoactive sexual desire disorder (HSDD).
        • The patient has female sexual interest/arousal disorder (FSIAD).
      • Clinical characteristics

        • The diagnosis is characterized by low sexual desire that causes marked distress or interpersonal difficulty.
        • The patient's symptoms of low sexual desire have been present for at least 6 months.At least 6 months
        • Exclusion of alternative causes

    • No duplicate target therapy: The patient will not use the requested agent in combination with another target agent in this program, such as Addyi or Vyleesi, for the requested indication.
    • No labeled contraindication: The patient does not have any FDA-labeled contraindication to the requested agent.

    Renewal Therapy

    Target agents will be approved for renewal when ALL of the following are met.

    Renewal therapy requirements

    • Previous approval: The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • Benefit coverage: The patient's benefit plan covers the requested agent.
    • Agent-specific eligibility

      • Vyleesi eligibility: The requested agent is Vyleesi and the patient is premenopausal.Premenopausal

    Concurrent use excluded: The requested agent must not be used in combination with another target agent in this program, such as Addyi or Vyleesi, for the requested indication. This requirement applies to both initial approval and renewal.

    FDA-labeled contraindications excluded: Coverage is not approved when the patient has any FDA-labeled contraindication to the requested agent. This safety requirement applies to both initial approval and renewal.

    Prior Authorization and Denial Risks

    Prior Authorization

    Initial Prior Authorization Required

    Initial prior authorization is required. Submit documentation showing that the requested agent is covered under the member’s benefit plan and that the patient meets the agent-specific eligibility and diagnosis requirements for HSDD/FSIAD.

    • Vyleesi: The patient must be premenopausal.
    • Addyi: The patient must be younger than 65 years and either female or a patient for whom Addyi is medically appropriate based on sex.
    • The patient must have acquired, generalized hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD).
    • The diagnosis must involve low sexual desire causing marked distress or interpersonal difficulty, with symptoms present for at least 6 months.
    • Document the patient’s prior treatment history and inadequate response to other treatment modalities; see the separate prior-treatment requirement below.
    Prior Authorization

    Renewal Prior Authorization Required

    Renewal requires prior approval through the plan’s prior authorization process and documentation that the patient continues to benefit clinically from the requested agent. The requested agent must remain covered and meet the applicable agent-eligibility requirements.

    Policy Background

    This policy establishes prior authorization and quantity-limit requirements for Addyi (flibanserin) and Vyleesi (bremelanotide) for acquired, generalized hypoactive sexual desire disorder (HSDD) and female sexual interest/arousal disorder (FSIAD). Approval requires a qualifying diagnosis characterized by low sexual desire causing marked distress or interpersonal difficulty, symptoms present for at least 6 months, and no specified medical, psychiatric, relationship, medication, or other drug-related cause. Initial and renewal requests must also meet agent-specific eligibility, benefit coverage, clinical, treatment-history, combination-use, and contraindication requirements.

    Clinical Definitions

    HSDD/FSIAD Clinical Characterization
    Qualifying conditionsAcquired, generalized hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD)
    Sexual desire characteristicLow sexual desire causing marked distress or interpersonal difficulty
    Minimum symptom durationAt least 6 months
    Excluded causesThe condition must not be due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or other drug substance

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial approval requires ALL applicable clinical criteria.

    Initial therapy clinical requirements

    • Agent-specific eligibility

      • Vyleesi eligibility: The requested agent is Vyleesi and the patient is premenopausal.Premenopausal
      • Addyi eligibility

        • The requested agent is Addyi and the patient is less than 65 years of age.Age <65 years
        • Sex appropriateness

    Renewal Therapy Criteria

    Renewal Therapy

    Renewal approval requires ALL of the following.

    Renewal requirements

    • Previous approval: The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • Benefit coverage: The patient's benefit plan covers the requested agent.
    • Agent-specific eligibility

      • Vyleesi eligibility: The requested agent is Vyleesi and the patient is premenopausal.

    Required Prior Treatment

    StepPrior treatment modalitiesRequired response
    1Education; modification of factors thought to be contributing to HSDD/FSIAD; and sex therapyInadequate response

    Program Quantity Limits

    Addyi (flibanserin tablets)
    Quantity limit30 tablets per 30 days
    Vyleesi (bremelanotide subcutaneous solution auto-injector pens)
    Quantity limit8 pens per 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyHypoactive Sexual Desire Disorder (HSDD) Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 15, 2026
    Next Review DateN/A
    Key ActionFor initial approval, document that the patient tried other treatment modalities and had an inadequate response.
    SourceLink
    On This Page
    General Coverage RequirementsPrior Authorization and Denial RisksPolicy BackgroundClinical DefinitionsInitial Therapy CriteriaRenewal Therapy CriteriaRequired Prior TreatmentProgram Quantity Limits
    HSDD/FSIAD is not due to a co-existing medical or psychiatric condition.
  1. HSDD/FSIAD is not due to problems within the relationship.
  2. HSDD/FSIAD is not due to the effects of a medication or other drug substance.
  3. Prior treatment modalities: The patient has tried and had an inadequate response to other treatment modalities, including education, modification of factors thought to be contributing to HSDD/FSIAD, and sex therapy.
  4. Addyi eligibility

    • Age: The requested agent is Addyi and the patient is less than 65 years of age.Age <65 years
    • Sex appropriateness

      • The patient's sex is female.
      • Addyi is medically appropriate for the patient's sex.
  5. Clinical benefit: The patient has had clinical benefit with the requested agent.
  6. No duplicate target therapy: The patient will not use the requested agent in combination with another target agent in this program, such as Addyi or Vyleesi, for the requested indication.
  7. No labeled contraindication: The patient does not have any FDA-labeled contraindication to the requested agent.
    • The patient must have been previously approved for the requested agent; patients without prior approval require initial evaluation review.
    • Vyleesi: The patient must be premenopausal.
    • Addyi: The patient must be younger than 65 years and either female or a patient for whom Addyi is medically appropriate based on sex.
    • Document continued clinical benefit with the requested agent.
    • Confirm that the requested agent will not be used with another target agent in the program, such as Addyi or Vyleesi, for the requested indication.
    • Confirm that the patient does not have an FDA-labeled contraindication to the requested agent.
    Step Therapy

    Prior Treatment Modalities Required

    Initial approval requires an inadequate response to other treatment modalities before the target agent is requested. Document the modalities tried and the patient’s response.

    • Examples include education, modification of factors thought to contribute to HSDD/FSIAD, and sex therapy.
    • The submitted documentation should explain that these modalities were tried and did not provide an adequate response.
    Denial Risk

    Failure to Meet Clinical or Safety Criteria

    Coverage may be denied when the clinical or safety criteria are not met, including when the diagnosis does not meet the program definition or when the requested agent is unsafe or used in a nonpermitted combination.

    • HSDD/FSIAD must not be attributable to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or other drug substance.
    • The patient must not use the requested agent in combination with another target agent in this program for the requested indication.
    • The patient must not have any FDA-labeled contraindication to the requested agent.
    • Requests that do not establish the required distress or interpersonal difficulty, symptom duration of at least 6 months, diagnosis, agent-specific eligibility, or continued clinical benefit for renewal may be denied.
    Denial Risk

    Quantity Limit May Result in Denial

    Requests exceeding the applicable program quantity limit may be denied. Verify the requested dose against the program limit before submitting the request.

    • The requested quantity must not exceed the program quantity limit.
    • Approval length is 6 months for initial requests and 12 months for renewal requests.
    • The patient's sex is female.
    • Addyi is medically appropriate for the patient's sex.
  8. Diagnosis and clinical criteria

    • Qualifying diagnosis

      • The patient has acquired, generalized hypoactive sexual desire disorder (HSDD).
      • The patient has female sexual interest/arousal disorder (FSIAD).
    • Clinical characteristics

      • The diagnosis is characterized by low sexual desire that causes marked distress or interpersonal difficulty.
      • The patient's symptoms of low sexual desire have been present for at least 6 months.At least 6 months
      • Exclusion of alternative causes

        • HSDD/FSIAD is not due to a co-existing medical or psychiatric condition.
        • HSDD/FSIAD is not due to problems within the relationship.
        • HSDD/FSIAD is not due to the effects of a medication or other drug substance.
      • Prior treatment modalities: The patient has tried and had an inadequate response to other treatment modalities, including education, modification of factors thought to be contributing to HSDD/FSIAD, and sex therapy.
  9. No duplicate target therapy: The patient will not use the requested agent in combination with another target agent in this program, such as Addyi or Vyleesi, for the requested indication.
  10. No labeled contraindication: The patient does not have any FDA-labeled contraindication to the requested agent.
  11. Premenopausal
  12. Addyi eligibility

    • The requested agent is Addyi and the patient is less than 65 years of age.Age <65 years
    • Sex appropriateness

      • The patient's sex is female.
      • Addyi is medically appropriate for the patient's sex.
  13. Clinical benefit: The patient has had clinical benefit with the requested agent.
  14. No duplicate target therapy: The patient will not use the requested agent in combination with another target agent in this program, such as Addyi or Vyleesi, for the requested indication.
  15. No labeled contraindication: The patient does not have any FDA-labeled contraindication to the requested agent.